Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co. (NYSE: MRK) is a global pharmaceutical leader with a 350-year legacy of medical innovation. This news hub provides investors and healthcare professionals with direct access to official announcements, financial disclosures, and research developments shaping the company's trajectory.
Track MRK's latest regulatory milestones, clinical trial results, and strategic partnerships through verified press releases and curated analysis. Our repository includes earnings call transcripts, FDA approval updates, and global health initiatives—all organized for efficient research and due diligence.
Key updates on therapeutic advancements in oncology, vaccines, and infectious diseases are maintained alongside financial performance data. Bookmark this page for real-time access to Merck's corporate communications and market-moving developments in the pharmaceutical sector.
Rhea-AI Summary
Merck (NYSE: MRK) has initiated MOBILIZE-1, its first Phase 3 clinical trial for V181, a novel quadrivalent dengue vaccine candidate. The study aims to evaluate the safety, immunogenicity, and efficacy of a single-dose vaccine designed to prevent dengue disease caused by all four dengue virus serotypes, regardless of prior exposure. The trial has begun recruitment in Singapore, marking a significant milestone in addressing this widespread mosquito-borne disease that threatens approximately half of the world's population. V181 could potentially offer a crucial single-dose preventive option for at-risk populations globally. Merck plans to conduct trials in various regions where dengue poses a significant health threat.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
-
Rhea-AI Summary
The FDA has approved Merck's (MRK) ENFLONSIA (clesrovimab-cfor), a preventive monoclonal antibody for RSV lower respiratory tract disease in infants. As the first RSV preventive with a uniform 105 mg dose regardless of weight, ENFLONSIA provides protection through 5 months. In the Phase 2b/3 CLEVER trial, ENFLONSIA demonstrated a 60.5% reduction in RSV-associated medically attended lower respiratory infections and an 84.3% reduction in RSV-associated hospitalizations compared to placebo. The drug is expected to be available before the 2025-2026 RSV season, with ordering beginning in July 2025. The CDC's Advisory Committee on Immunization Practices will meet to discuss recommendations for ENFLONSIA's use in infants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
-
Rhea-AI Summary
Merck (MRK) announced positive topline results from two Phase 3 trials (CORALreef HeFH and CORALreef AddOn) evaluating enlicitide decanoate, a potential first-in-class oral PCSK9 inhibitor for hyperlipidemia treatment. Both trials met primary and key secondary endpoints, showing significant LDL-C reductions compared to placebo and other oral non-statin therapies. The CORALreef HeFH trial demonstrated efficacy in patients with heterozygous familial hypercholesterolemia, while CORALreef AddOn showed superior results versus ezetimibe and bempedoic acid. The drug showed a favorable safety profile with no meaningful differences in adverse events. The CORALreef program aims to enroll approximately 17,000 patients across several trials, including ongoing CORALreef Lipids and CORALreef Outcomes studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
Rhea-AI Summary
Merck (NYSE: MRK) announced that its chairman and CEO Robert M. Davis, along with Dr. Dean Y. Li, executive vice president and president of Merck Research Laboratories, will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference. The event is scheduled for Tuesday, June 10, 2025, at 10:00 a.m. EDT. The presentation will be accessible via live audio webcast to investors, analysts, media representatives, and the general public.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
-
Rhea-AI Summary
Merck announced significant results from the Phase 3 ASCENT-04/KEYNOTE-D19 study showing KEYTRUDA plus Trodelvy reduced disease progression or death risk by 35% compared to KEYTRUDA plus chemotherapy in first-line PD-L1+ metastatic triple-negative breast cancer (TNBC). The combination achieved median progression-free survival of 11.2 months versus 7.8 months with KEYTRUDA plus chemotherapy. The study demonstrated higher objective response rate (59.7% vs 53.2%) and longer duration of response (16.5 months vs 9.2 months) for KEYTRUDA plus Trodelvy. The safety profile was consistent with known profiles of both drugs, with no new safety signals identified. This marks the first pivotal Phase 3 trial showing superiority of KEYTRUDA plus a TROP2 antibody-drug conjugate versus standard care in first-line metastatic TNBC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Merck announced promising Phase 1 KANDLELIT-001 trial results for MK-1084, their investigational KRAS G12C inhibitor, in treating advanced colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) with KRAS G12C mutations. The drug showed encouraging antitumor activity both as monotherapy and in combinations. In CRC, MK-1084 demonstrated confirmed response rates of 38% as monotherapy, 46% when combined with cetuximab, and 38% with cetuximab plus chemotherapy. For NSCLC, response rates were 38% as monotherapy, notably 77% when combined with KEYTRUDA in untreated metastatic cases, and 53% with KEYTRUDA plus chemotherapy. The drug maintained a manageable safety profile across all treatment arms, with treatment-related adverse events ranging from 58% in monotherapy to 97% in combination therapies. Merck plans to advance MK-1084 to Phase 3 trials for both CRC and NSCLC treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
Rhea-AI Summary
Merck announced promising results from the Phase 2/3 waveLINE-003 study of zilovertamab vedotin combined with R-GemOx for treating relapsed/refractory DLBCL. At the 1.75 mg/kg dose, the combination achieved a 56.3% objective response rate, including 8 complete responses and 1 partial response in 16 patients. The study evaluated three dose levels (1.5, 1.75, and 2.0 mg/kg), with 1.75 mg/kg selected as the recommended Phase 2 dose based on efficacy and safety data. Treatment-related adverse events occurred in 98% of patients, with Grade ≥3 events in 63%. The drug is currently being evaluated in multiple Phase 2 and 3 trials, including waveLINE-010, waveLINE-007, and waveLINE-011, for various DLBCL treatment settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
-
Rhea-AI Summary
Daiichi Sankyo and Merck (MRK) have voluntarily withdrawn their Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). The withdrawal follows topline overall survival results from the HERTHENA-Lung02 phase 3 trial that failed to meet statistical significance. While the trial showed statistically significant progression-free survival (PFS), the overall survival data did not reach the required threshold. The decision is unrelated to a previous Complete Response Letter from June 2024 regarding third-party manufacturing facility inspection findings. The companies will present detailed trial results at the 2025 ASCO Annual Meeting. The safety profile remained consistent with previous trials, with no new safety signals identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
-
Rhea-AI Summary
Merck (NYSE: MRK) has announced its quarterly dividend payment for Q3 2025. The company's Board of Directors has declared a dividend of $0.81 per share of common stock. The dividend will be paid on July 8, 2025, to shareholders who are on record as of the close of business on June 16, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
Rhea-AI Summary
Merck (MRK) and Daiichi Sankyo have initiated the IDeate-Esophageal01 Phase 3 trial for ifinatamab deruxtecan (I-DXd), a potential first-in-class B7-H3 directed antibody drug conjugate. The trial will evaluate I-DXd versus standard chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have progressed after platinum therapy and immunotherapy. ESCC represents 90% of global esophageal cancers with a dire 15-20% five-year survival rate. The trial's initiation follows promising results from the IDeate-PanTumor01 phase 1/2 trial presented at ESMO 2022 and 2023, which demonstrated encouraging responses in heavily pretreated ESCC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
FAQ
What is the current stock price of Merck & Co (MRK)?
The current stock price of Merck & Co (MRK) is $83.71 as of July 9, 2025.
What is the market cap of Merck & Co (MRK)?
The market cap of Merck & Co (MRK) is approximately 205.4B.
Merck & Co
NYSE:MRK
MRK Rankings
MRK Stock Data
205.43B
2.51B
0.07%
80.45%
1.62%
Drug Manufacturers - General
Pharmaceutical Preparations
United States
RAHWAY